JP4755742B2 - 医薬最終処方物におけるナノディスパージョンの使用 - Google Patents

医薬最終処方物におけるナノディスパージョンの使用 Download PDF

Info

Publication number
JP4755742B2
JP4755742B2 JP12999099A JP12999099A JP4755742B2 JP 4755742 B2 JP4755742 B2 JP 4755742B2 JP 12999099 A JP12999099 A JP 12999099A JP 12999099 A JP12999099 A JP 12999099A JP 4755742 B2 JP4755742 B2 JP 4755742B2
Authority
JP
Japan
Prior art keywords
polyoxyethylene
nanodispersion
nano
fatty acid
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP12999099A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11335266A5 (https=
JPH11335266A (ja
Inventor
ヴェルナー ズーペルザクソ アンドレアス
ゲオルク ヴェーダー ハンス
ヒューグリン ディートマー
フリードリヒ レディング ヨアヒム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Holding AG filed Critical Ciba Holding AG
Publication of JPH11335266A publication Critical patent/JPH11335266A/ja
Publication of JPH11335266A5 publication Critical patent/JPH11335266A5/ja
Application granted granted Critical
Publication of JP4755742B2 publication Critical patent/JP4755742B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP12999099A 1998-05-11 1999-05-11 医薬最終処方物におけるナノディスパージョンの使用 Expired - Lifetime JP4755742B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98810422.0 1998-05-11
EP98810422 1998-05-11

Publications (3)

Publication Number Publication Date
JPH11335266A JPH11335266A (ja) 1999-12-07
JPH11335266A5 JPH11335266A5 (https=) 2006-06-22
JP4755742B2 true JP4755742B2 (ja) 2011-08-24

Family

ID=8236078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP12999099A Expired - Lifetime JP4755742B2 (ja) 1998-05-11 1999-05-11 医薬最終処方物におけるナノディスパージョンの使用

Country Status (20)

Country Link
US (2) US7081253B2 (https=)
EP (1) EP0956853B1 (https=)
JP (1) JP4755742B2 (https=)
KR (1) KR100622285B1 (https=)
CN (1) CN1220483C (https=)
AR (1) AR019274A1 (https=)
AT (1) ATE312597T1 (https=)
AU (1) AU767896B2 (https=)
BR (1) BRPI9902068B8 (https=)
CZ (1) CZ166999A3 (https=)
DE (1) DE59912910D1 (https=)
ES (1) ES2253871T3 (https=)
HU (1) HUP9901570A2 (https=)
ID (1) ID22565A (https=)
MY (1) MY133019A (https=)
PL (1) PL332934A1 (https=)
RU (1) RU2224505C2 (https=)
SG (1) SG71923A1 (https=)
TW (1) TWI241915B (https=)
ZA (1) ZA993200B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230270691A1 (en) * 2020-06-01 2023-08-31 Advent Therapeutics, Inc. Pharmaceutical compositions comprising insoluble active ingredients

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908309D0 (en) * 1999-04-12 1999-06-02 Phares Pharm Res Nv Lipid aggregate forming compositions and their use
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
TW586945B (en) * 2001-01-12 2004-05-11 Novartis Ag Lens care product containing dexpanthenol
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
RU2200558C1 (ru) * 2002-04-23 2003-03-20 Нестерук Владимир Викторович Лекарственное средство, содержащее финастерид
AT6609U3 (de) * 2003-04-07 2004-04-26 Unipack Ges M B H Abfuell Und Verfahren zum herstellen einer klaren lecithin enthaltenden oralen zubereitung
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
WO2005117830A1 (en) * 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
TWI350183B (en) * 2003-12-31 2011-10-11 Ind Tech Res Inst A liposome and a preparation method
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
DE112006001898B4 (de) * 2005-07-21 2013-05-08 National Institute For Materials Science Vorrichtung zur Inhalation von Arzneimitteln
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
NZ572601A (en) 2006-03-29 2012-03-30 Univ Wayne State Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
JP4840031B2 (ja) 2006-08-31 2011-12-21 ソニー株式会社 ナビゲーション装置、ナビゲーション処理方法及びナビゲーション処理プログラム
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
CL2008000037A1 (es) * 2007-01-16 2008-10-10 Bayer Consumer Care Ag Solucion coloidal que comprende al menos un ingrediente activo, al menos una molecula formadora de membrana y al menos un componente espumante; procedimiento para fabricar la solucion coloidal; y su uso para tratar trastornos dermatologicos.
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
CN100536826C (zh) * 2007-12-28 2009-09-09 清华大学 一种绵羊油纳米乳液及其制备方法和应用
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
DE202010004750U1 (de) 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
CN102277748A (zh) * 2010-06-12 2011-12-14 罗莱家纺股份有限公司 纳米维生素微胶囊整理剂的使用方法
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP3583954A1 (en) * 2018-06-19 2019-12-25 neubourg skin care GmbH Nanodispersions of birch bark extract, electrospun fibers containing such nanodispersions and their use for the treatment of wounds
EP4065108B1 (en) 2019-11-25 2025-08-06 The Johns Hopkins University Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors
CN111388744B (zh) * 2020-01-15 2021-05-18 华中科技大学 一种凝胶贮库及其制法与制备术后止血制剂的应用
CA3170810A1 (en) * 2020-02-11 2021-08-19 Advent Therapeutics Inc. Compositions of vitamin a palmitate, processes for their preparation, uses and methods comprising them
US20230310386A1 (en) * 2020-05-20 2023-10-05 Intervet Inc. Injectable pharmaceutical compositions and uses thereof
MX2022016437A (es) 2020-06-30 2023-01-30 Chong Kun Dang Pharmaceutical Corp Composicion inyectable que comprende un analogo de gnrh.
WO2024165166A1 (en) 2023-02-10 2024-08-15 Tetra Pharm Technologies A cannabinoid-based o/w emulsification system for oral administration targeting endocannabinoid receptors
WO2024208434A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Pressurized nanoemulsion
WO2024208433A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3150990A1 (de) 1981-12-23 1983-06-30 A. Nattermann & Cie GmbH, 5000 Köln Neue pflanzenschutzmittelsuspensionskonzentrate
US4675193A (en) * 1983-10-31 1987-06-23 Borden, Inc. Cheese-flavored substance and method of producing same
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
US4965357A (en) 1986-08-07 1990-10-23 Medice Chem.-Pharm. Fabrik Putter Gmbh & Co. Kg 2,5,6-substituted N1 -alkylpyrimidines
DE3852409T2 (de) 1987-01-27 1995-04-20 Vestar Inc Aus Phospholipiden bestehende Darreichungsform für wasserunlösliche Wirksubstanzen.
DE68917544T2 (de) 1988-06-20 1994-12-15 Shiseido Co Ltd Durchsichtiges Präparat.
CA1337397C (en) * 1988-09-29 1995-10-24 Hideo Nakajima Emulsified composition
FR2648462B1 (fr) 1989-06-15 1994-01-28 Oreal Procede pour ameliorer l'efficacite therapeutique de corticosteroides liposolubles et composition pour la mise en oeuvre de ce procede
CH677886A5 (https=) * 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
ZA925581B (en) * 1991-07-26 1993-05-14 Smithkline Beecham Corp Pharmaceutical microemulsions.
US5260065A (en) 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
CH685674A5 (de) 1993-12-19 1995-09-15 Marigen Sa Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit pharmakologisch wirksamen Estern von Apocarotinolen.
ES2094688B1 (es) * 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
PE52896A1 (es) * 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
EP0711557A1 (de) 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733358A3 (de) * 1995-03-21 1998-05-20 Novartis AG Intravenös applizierbare Nanosuspensionen
WO1996037192A1 (en) * 1995-05-26 1996-11-28 Vesifact Ag Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids
DE19522693A1 (de) 1995-06-22 1997-01-02 Dianorm G Maierhofer Gmbh Zusammensetzung zur Herstellung feindisperser Systeme und Verfahren zu ihrer Herstellung
JP3508314B2 (ja) * 1995-08-18 2004-03-22 大正製薬株式会社 ビタミンｃを配合した液剤
AU7689996A (en) * 1995-12-12 1997-07-03 Vesifact Ag Cortisone spray for topical administration
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
DE59710082D1 (de) * 1996-12-13 2003-06-18 Vesifact Ag Baar Kosmetische Präparate in Form einer Nanodispersion
US6028067A (en) * 1997-12-05 2000-02-22 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230270691A1 (en) * 2020-06-01 2023-08-31 Advent Therapeutics, Inc. Pharmaceutical compositions comprising insoluble active ingredients

Also Published As

Publication number Publication date
EP0956853B1 (de) 2005-12-14
EP0956853A2 (de) 1999-11-17
AU2805099A (en) 1999-11-18
PL332934A1 (en) 1999-11-22
US7081253B2 (en) 2006-07-25
ID22565A (id) 1999-11-11
JPH11335266A (ja) 1999-12-07
HU9901570D0 (en) 1999-07-28
SG71923A1 (en) 2000-04-18
CN1235017A (zh) 1999-11-17
US7871642B2 (en) 2011-01-18
ATE312597T1 (de) 2005-12-15
RU2224505C2 (ru) 2004-02-27
BRPI9902068B8 (pt) 2021-05-25
MY133019A (en) 2007-10-31
TWI241915B (en) 2005-10-21
CZ166999A3 (cs) 1999-11-17
BR9902068A (pt) 2000-06-06
CN1220483C (zh) 2005-09-28
KR19990088156A (ko) 1999-12-27
EP0956853A3 (de) 2000-01-05
KR100622285B1 (ko) 2006-09-11
DE59912910D1 (de) 2006-01-19
AR019274A1 (es) 2002-02-13
AU767896B2 (en) 2003-11-27
BR9902068B1 (pt) 2014-10-29
US20060292191A1 (en) 2006-12-28
ZA993200B (en) 1999-11-11
ES2253871T3 (es) 2006-06-01
US20030190347A1 (en) 2003-10-09
HUP9901570A2 (hu) 2001-06-28

Similar Documents

Publication Publication Date Title
JP4755742B2 (ja) 医薬最終処方物におけるナノディスパージョンの使用
TWI440477B (zh) 兩相微泡組合物用於製備治療具人類乳突病毒狀態之低度鱗狀上皮內病變之藥物的用途
WO1999044594A1 (fr) Emulsions huileuses destinees a etre administrees par inhalation
PT981328E (pt) Composição formadora de uma emulsão para um composto taxóide.
JPH08268893A (ja) スタウロスポリン誘導体の静脈内投与のための医薬組成物
JP2003513019A (ja) トコール可溶性治療剤の組成物
US20170182133A1 (en) Compositions for providing agents that degrade in water
PT711148E (pt) Vesicula lipidica multilamelar bifasica
BR112012015433B1 (pt) Composição farmacêutica substancialmente anidra para aplicação cutânea
JPH02203A (ja) 薬物担体
JP4630658B2 (ja) 疎水性薬剤の吸収および胃腸の生物学的利用能を向上させるための方法および調剤
CN101524329A (zh) 双环醇亚微乳及其制备方法
JPH07503952A (ja) リポソームピロキシカム組成物
ES2210035T3 (es) Composiciones farmaceuticas destinadas a una administracion por via oral.
JPS61204136A (ja) 血液脳関門通過性医薬品組成物
WO1991007973A1 (en) Fat emulsion
JP3470131B2 (ja) 持効性点鼻剤
KR100524700B1 (ko) 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용약제 조성물
JP2616240B2 (ja) 脂肪乳剤の製法
JPS61221114A (ja) 脂肪乳剤
MXPA99004334A (es) Uso de nanodispersiones en formulaciones farmaceuticas finales
JPH04145020A (ja) ニトログリセリンのリポゾーム及びそれを含む製剤
JPH0489430A (ja) 低血圧維持剤
WO2002009670A1 (en) Liquid or semi-solid pharmaceutical excipient and pharmaceutical composition comprising the same
JPH03209329A (ja) 医療用製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110203

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110307

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110510

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110530

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140603

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term